Cutler Group LP Neurocrine Biosciences Inc Put Options Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 Apr 14, 2022	SELL	$72.45 - $94.81 $883,890 - $1.16 Million	-12,200 Reduced 96.83%	400 $0
Q2 2021 Jul 19, 2021	BUY	$89.43 - $102.27 $858,528 - $981,792	9,600 Added 320.0%	12,600 $37,000
Q1 2021 Apr 26, 2021	BUY	$87.57 - $119.4 $43,785 - $59,700	500 Added 20.0%	3,000 $27,000
Q1 2020 May 07, 2020	SELL	$75.11 - $113.76 $368,039 - $557,424	-4,900 Reduced 66.22%	2,500 $54,000
Q2 2019 Aug 09, 2019	SELL	$72.24 - $91.27 $325,080 - $410,715	-4,500 Reduced 37.82%	7,400 $136,000
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $27,724 - $36,612	400 Added 3.48%	11,900 $140,000
Q4 2018 Feb 05, 2019	BUY	$68.32 - $124.36 $416,751 - $758,596	6,100 Added 112.96%	11,500 $227,000
Q3 2018 Nov 07, 2018	SELL	$98.88 - $125.85 $59,328 - $75,510	-600 Reduced 10.0%	5,400 $47,000
Q2 2018 Aug 10, 2018	SELL	$75.3 - $105.99 $564,750 - $794,925	-7,500 Reduced 55.56%	6,000 $2,000
Q1 2018 May 11, 2018	SELL	$75.88 - $92.43 $1.11 Million - $1.35 Million	-14,600 Reduced 51.96%	13,500 $31,000
Q4 2017 Jan 17, 2018	BUY	$58.53 - $77.59 $169,737 - $225,011	2,900 Added 11.51%	28,100 $69,000
Q3 2017 Oct 17, 2017	BUY	$47.97 - $61.28 $1.21 Million - $1.54 Million	25,200	25,200 $56,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.